Connective tissue growth factor

• US 7,384,634 B2
• Filed: 01/07/2003
• Issued: 06/10/2008
• Est. Priority Date: 08/30/1991
• Status: Expired due to Fees

• Current Assignee: University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Bradham, Douglass M. Jr., Grotendorst, Gary R.
• Primary Examiner(s): Spector; Lorraine
• Application Number:
  US10/338,587
• Publication Number:
  US 20040005319A1
• Time in Patent Office: 1,981 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/574 for cancer

Abstract

The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF and polynucleotides regulating CTGF expression. The invention also provides agents that modulate CTGF and therapeutic methods for using the agents. Also provided are diagnostic methods for using CTGF and assays for identifying agents which affect the expression of CTGF polynucleotide.

Claims

1. A method of treating a disorder selected from the group consisting of pulmonary fibrosis, kidney fibrosis, tumor formation and growth, and glaucoma comprising administering a therapeutic amount of an agent that modulates CTGF level or activity to a subject in need thereof, wherein the agent is an antibody which selectively binds to CTGF and does not cross-react with PDGF.

3. The method of claim 1 or 2, wherein the antibody is a monoclonal or a polyclonal.

4. The method of claim 1 or 2, wherein the disorder is pulmonary fibrosis.

5. The method of claim 1 or 2, wherein the disorder is kidney fibrosis.

6. The method of claim 1 or 2, wherein the disorder is tumor formation and growth.

7. The method of claim 1 or 2, wherein the disorder is glaucoma.

2. A method for ameliorating a disorder selected from the group consisting of pulmonary fibrosis, kidney fibrosis, tumor formation and growth, and glaucoma comprising treating a subject having the disorder, at the site of the disorder, with a CTGF reactive agent, wherein the reactive agent comprises an antibody which selectively binds to CTGF and does not cross-react with PDGF.